The blood cells of patients with paroxysmal nocturnal hemoglobinuria (PNH) have abnormal interactions with complement. The activity of the alternative pathway C3 convertase on the platelets of 9 out of 19 patients with PNH was elevated. 10 patients had C3 convertase activity within the normal range even though 80-95% of their platelets lacked the complement regulatory protein decay accelerating factor (DAF) that is absent from the affected blood cells in PNH. PNH and normal platelets released factor H when C3 was bound to their surfaces. This may account for the apparent regulation of C3 convertase activity on platelets that lack DAF. The abnormal uptake of the membrane attack complex of complement by PNH III erythrocytes was not seen in PNH platelets. "'Indium-labeled platelet survival times were normal in five of eight patients, which suggests that the lack of the membrane attack complex defect results in normal platelet survival in PNH.
Introduction
Paroxysmal nocturnal hemoglobinuria (PNH)' is a hematopoietic stem cell disorder characterized by an increased sensitivity of the blood cells to complement-mediated lysis, hematocytopenia, and a propensity toward intravascular coagulation (1) (2) (3) . The PNH erythrocyte may be abnormal in one or two of its interactions with complement. PNH II erythrocytes show an inability to regulate the C3 convertases formed on the cell surface (4, 5) . As a result, these cells are three to five times more sensitive to complement than normal erythrocytes (6) . PNH III erythrocytes have increased sensitivity to the terminal components of complement, the membrane attack complex (7) . This defect may actually be twofold. PNH 1. Abbreviations used in this paper: CLS, complement lysis sensitivity; CoVF, cobra venom factor; CoVFBb, complexes formed from CoVF and activated factor B; DAF, decay accelerating factor, FITC, fluorescein isothiocyanate; GVB, veronal-buffered saline containing 0.1% gelatin; PFA, paraformaldehyde; PNH, paroxysmal nocturnal hemoglobinuria.
normal red cell before a lytic pore is created (8) . In addition, when membrane attack complexes are generated in serum, they readily bind to the surface ofPNH III cells but not to the surface of normal cells (9, 10) . Having both the C3 convertase and terminal complex defects makes the PNH III red cell 15-25 times more susceptible to complement lysis than normal red cells (6) .
Recently, the PNH erythrocyte (11, 12) as well as the PNH platelet, monocyte, and granulocytes (13) , have been found to lack decay accelerating factor (DAF), a protein that regulates both the classical and alternative pathway C3 convertases on the surface of erythrocytes (14) (15) (16) . The deficiency of this molecule seems to be responsible for the defect in the regulation of the activation of C3 shared by PNH II and PNH III cells. However, although PNH II red cells reconstituted with purified DAF lose their increased susceptibility to complement, PNH III cells remain sensitive to the membrane attack complex (17) . The molecular basis for the terminal complex defect of PNH III erythrocytes remains to be elucidated.
The platelets of patients with PNH are also abnormally sensitive to the lytic action of complement when complement is activated by platelet-specific antibody (18) . The in vivo significance of this observation is not clear. Although some patients with PNH have a reduced platelet count, generally in the context of pancytopenia, many have platelet counts well within normal range. It is not known whether PNH platelets also have two defects in complement regulation similar to the erythrocyte. Using antibody-binding assays, we have measured DAF in the platelets of 20 patients with PNH. We have determined the relative percentage of abnormal platelets in the total platelet population in these patients and compared this with the relative percentage of abnormal erythrocytes. We have measured the activity of stabilized alternative pathway C3 convertases formed on the surface of PNH platelets as well as the ability of the PNH platelet to take up membrane attack complexes under the conditions of reactive lysis. To assess the impact of defects in complement regulation on the survival of platelets, "'In-labeled platelet survival studies have been performed on eight patients with PNH.
Methods
Buffers, complement components, and antisera. All experiments were carried out in either veronal-buffered saline (5.0 mM sodium barbital, 0.15 M NaCl, and 0.1% gelatin [pH 7.5]) containing 0.0 15 M EDTA (GVB-EDTA) or veronal-buffered saline containing 0.15 mM calcium chloride and 0.5 mM magnesium chloride (GVB++) or 2.5 mM magnesium alone (GVB+). Cobra venom factor (CoVF; reference 19), C3 (20) , factor B (4), factor D (21), C3 nephritic factor (22) , and DAF (15) were purified using previously described methods. Purified thrombin was the gift of Dr 50 Mg factor B, and crude factor D for 30 min at 37°C. Immediately after washing three times in PBS, the platelets were resuspended in I ml PBS containing 1% paraformaldehyde (PFA) and incubated at room temperature for 1 h. After washing three times in GVB-EDTA to block unreacted aldehyde groups, the platelets were stained for flow cytometry as described above using goat anti-factor H or rabbit anti-C3c (both from Calbiochem-Behring Corp.) and the appropriate FITC-conjugated second antibodies. Control platelets were prepared using PFA-fixed platelets that had been exposed to complement components. Controls for antibody binding were performed using nonimmune sera.
Thrombin-stimulated factor H release was assessed by treating platelets at 5 X 108/ml in GVB-EDTA with 100 U/ml thrombin for 20 min at 37°C. The platelets were then fixed in PFA and stained as described above.
Quantitation ofplatelet factor H. The amount of factor H released by thrombin-stimulated or detergent-solubilized platelets was measured by a radioimmunoassay described in detail elsewhere (Devine, (27) , as modified by Heaton et al. (28) . There was no loss of platelets during the labeling procedure. 200 MCi of "'In-labeled autologous platelets were injected intravenously and serial blood samples were obtained 15 min and 2 h after injection, then everydardization in Hematology (29 Images ofthe anterior and posterior chest and anterior and posterior abdomen were obtained 24 h after injection using a large crystal scintillation camera fitted with a medium energy collimator. Both gamma photon peaks of "'In (at 173 and 247 keV) were summed and each image was acquired for 300 s.
Results
We have studied the platelets of 20 (Fig. 1) . For each patient studied, there was a greater population of abnormal (DAF-deficient) platelets than abnormal erythrocytes. The binding of anti-DAF to normal donor platelets was highly heterogeneous (Fig. 2 A) . Most patients had platelets which bound little if any anti-DAF (Fig. 2 C) . Even in those four PNH patients whose platelets showed significant anti-DAF binding there was never the intensity of staining seen in normal platelets (Fig. 2 B) .
By Western blot analysis, the platelets ofpatients with >80% DAF-negative platelets by fluorescence analysis did not contain cryptic pools of DAF (Fig. 3) . Using this method, DAF was readily detected in normal platelets (Fig. 3, lane 1) .
The activity of the alternative pathway C3 convertase was measured on the surface of normal and PNH platelets to determine the effect of DAF deficiency on the regulation of this enzyme complex. PNH platelets did not bind fluid phase C3b more readily than normal platelets because similar amounts of monoclonal anti-C3c bound to normal donor or PNH platelets, which were reacted with fluid phase CoVF-factor Bb complexes and C3 (Table I) (Fig. 4) . 10 of 19 patients had normal C3 convertase activity, while 9 had elevated activity. C3 convertase activity was also measured on the platelets of four patients without C3 nephritic factor stabilization. Although the conversion ratios for both normal and PNH platelets were lower than those obtained with stabilized convertases, the pattern of elevated convertase activity on the platelets of only some of the PNH patients was consistent with the results of experiments with stabilized C3 convertases. Three of the four patients had elevated convertase activity with a stabilized convertase. Without the addition of C3 nephritic factor, the convertase activity was 2.9, 3.6, and 4.7 times that seen on normal platelets run in parallel experiments. The other patient had platelets on which a stabilized C3 convertase had normal activity. When the experiment was performed with this person's platelets without C3 nephritic factor, the convertase activity was 0.9 times that of the normal platelet controls.
Because the presence of DAF on the platelets could account for the apparent regulation of the C3 convertase activity on the platelets of some PNH patients, the C3 convertase activity was compared with the percentage of DAF-negative platelets ( 5). 8 of the 10 patients with normal convertase activity had >70% DAF-negative platelets by flow cytometry analysis.
When platelets were incubated with C3, factor B, factor D, CoVF, and magnesium, C3b was bound to the platelet surface. Some of the C3b binds factor B to form the alternative pathway C3 convertase on the platelet surface. The deposition of C3 by this technique triggered the release of factor H from the platelet. Factor H then became bound to the platelet surface and was detected by flow cytometry. Fig. 6 shows factor H release from normal platelets in response to C3 deposition. Very similar staining patterns were seen when PNH platelets contained platelet-bound C3 (Fig. 7) rounding medium; however, factor H did not bind back to the platelet surface in the absence of platelet-bound C3b (Fig. 6) .
We have quantitated the amount of factor H released from the platelets of five patients with PNH 
tive pathway C3 convertase activity and the percentage of DAF-negative platelets for patients with PNH. C3 convertase activity was assessed as described in Fig. 4 . The *.
percentage of DAF-negative plate- P> 0.5) (Fig. 8) . However, the monoclonal anti-poly C9 readily detected the increased uptake of membrane attack complexes by PNH III erythrocytes under identical reactive lysis conditions. In addition, PNH platelets exposed to reactive lysis conditions bound '25I-labeled anti-C3c in amounts similar to normal platelets (data not shown).
Ofthe eight patients who participated in "'In-labeled platelet survival studies, five had normal platelet survival, while three had decreased survival (Table II) . Of the three with decreased Normal 200-300,000 180-200 60-70 1000-1500 0
Platelets were isolated from the patient's peripheral blood and labeled with "'In oxine. After the labeled platelets were given back to the patient, blood samples were drawn at 15 min, 2 h, and every 12 h after injection. Survival was calculated using the maximum likelihood estimate of the integer-ordered gamma function (29) . * Splenomegaly present.
Not done. . 1. platelet antibody ( 18) than are normal platelets. The interactions of platelets with the alternative pathway of complement are not as well understood. Studies from this laboratory using CoVFtreated whole serum and quantitative antiglobulin consumption assays for platelet-bound C3 indicate that PNH platelets bind more C3 than do normal platelets (31) .
To study the interactions of normal and PNH platelets with complement components in the absence ofother serum proteins, we used purified components and monoclonal antibodies specific for the C3c region of C3. We have demonstrated that the C3 convertase activity on the platelets of many patients with PNH was not greater than that on normal platelets. This could not be attributed to the presence ofDAF either on the platelet surface or in internal pools that might be expressed when complement binds to the platelet. The platelets of 16 of 20 patients examined were nearly all DAF-deficient. Because platelets that were lacking in DAF did not bind abnormal amounts of C3, DAF may not play as pivotal a role in the regulation ofthe alternative pathway C3 convertase on the platelet as it does on the red blood cell surface (1 1, 12 ). However, DAF may be crucial to the regulation of the classical pathway C3 convertase, C4b2a, on the platelet surface. The absence ofthis regulatory protein on PNH platelets may explain the increased susceptibility of the PNH platelet to lysis by antibody and complement (18, 31) . In fact, preliminary data obtained on some of the same patients reported in this study indicate that when complement is activated by antibody in a whole serum system, PNH platelets bind both more C3 and more C9 than normal platelets. The hypothesis that DAF is not crucial in the regulation ofthe alternative pathway C3 convertase on platelets is further supported by the observation that when C3 was deposited onto the surface ofplatelets via the alternative pathway, the platelets of both normal donors and patients with PNH released factor H, a plasma protein that performs a similar function to DAF. Factor H became bound to the platelet surface only when C3 was present on the platelet. Factor H released by thrombin stimulation did not bind to the platelet surface in the absence of platelet-bound C3. The platelet, therefore, appears to have a second mechanism to regulate surface-bound alternative pathway C3 convertases. Other complement components in addition to factor H (32) have been described in platelets, including Cl inhibitor (33) and factor D (32) . Whereas the intracellular localization of factor H has not yet been determined, the other two complement components appear to reside in the platelet alpha granules.
In PNH platelets, the total amount of factor H present appears to be lower than that in normal platelets. The factor H released by thrombin-stimulated platelets of two patients with increased C3 convertase activity was markedly deficient, although the total amount of factor H contained in these platelets was equivalent to that amount readily released from PNH platelets with normal C3 convertase activity. In addition, we report elsewhere that the inhibition offactor H release from normal platelets markedly enhances C3 convertase activity. Therefore, it appears that some PNH platelets may be unable to release a sufficient amount of factor H to regulate the activity of the alternative pathway C3 convertase. The reason that this occurs in only some of the PNH patients studied remains to be elucidated.
Previous studies from both our laboratory (31) and others (34) on the interaction ofthe alternative pathway of complement with the platelets in PNH were all performed using whole serum systems. The data reported in this study support the observation of Zimmerman and Kolb (34) that the platelets in PNH do not take up more C3 than normal platelets when exposed to CoVFtreated serum. However, these workers reported an increased uptake ofC8, presumably in the form ofmembrane attack complex by the platelets of one PNH patient under the same conditions. We did not see any increase in the uptake of membrane attack complexes under our experimental conditions, which differed somewhat from those of Zimmerman and Kolb (34) , particularly with regard to the presence of EDTA in the reaction mixture. In whole serum systems, the interactions ofthe platelets with activated coagulation factors, especially thrombin, as well as with complement components must be taken into consideration. The presence of thrombin has been shown to markedly affect the interaction of platelets with complement (35, 36).
Platelets can actively rid themselves of surface-bound membrane attack complexes by a calcium-dependent shedding process similar to the patching and capping phenomena seen in nucleated cells (37) . In this investigation, this process was inhibited by performing the experiments in the presence of EDTA. Under these conditions, we have demonstrated that the platelets from patients with PNH III erythrocytes do not take up membrane attack complexes that are generated in the fluid phase. However, the PNH III erythrocyte will take up large amounts of this complex resulting in cell lysis (9, 10) . Because this is most likely the mechanism that contributes to the severely shortened in vivo survival ofthe PNH III erythrocyte, it follows that we and others (18) have found in vivo platelet survival was normal in most PNH patients. This is reflected in the observed percentages of abnormal erythrocytes and abnormal platelets in the peripheral blood of patients with PNH. Because the erythrocyte lifespan is shortened and the platelet lifespan is normal or nearly so, the percentage of abnormal platelets may more accurately reflect the extent ofproliferation ofthe abnormal PNH clone. Shortened platelet survival time was only seen in those patients who had splenomegaly or in the one patient in the study who was entering an aplastic crisis.
In addition, the PNH III erythrocyte is markedly sensitive to lysis by complement because the cells will bear fewer of the membrane attack complexes of complement than normal erythrocytes before they lyse. Although we do not have direct evidence that this is also the case for PNH platelets, it would explain the observation that PNH platelets are more susceptible to complement lysis when complement is activated at the platelet surface, e.g., by anti-platelet antibody (18) .
